Dr. Heimbach on Liver Transplant Criteria in HCC

Video

Julie K. Heimbach, MD, discusses the criteria for liver transplantation in patients with hepatocellular carcinoma.

Julie K. Heimbach, MD, a transplant surgeon and the surgical director of Liver Transplantation at Mayo Clinic, discusses the criteria for liver transplantation in patients with hepatocellular carcinoma (HCC).

Numerous changes in liver transplantation criteria have taken place over several years, both overall and specific to HCC, according to Heimbach. These changes began in 2018 when standard downstaging criteria were adopted. Previously, patients who were outside of standard Milan criteria had to go through an appeal process in order to undergo transplant, but this is no longer the case, says Heimbach. Patients who are outside of the Milan criteria but have been successfully downstaged can now go through a standard process for transplant, she explains.

Additionally, another policy change was adopted for patients with exceptions in HCC, which comprises approximately 70% of the exceptions. 

Thus far, a standard patient with HCC who is meeting transplant criteria and is going to have an exception previously were given a score that increased every 3 months, she says. Since May 2020, if a patient is given a score that has started just below the median where they were offered transplant, their score stays there, Heimbach says. While it starts higher than it used to, it doesn't go up, Heimbach concludes.

Related Videos
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Michael J. Overman, MD
Manish A. Shah, MD, director, Gastrointestinal Oncology Program, Weill Cornell Medicine; chief, Solid Tumor Service, co-director, Center for Advanced Digestive Disease, NewYork Presbyterian
Katrina S. Pedersen, MD, MS
Efrat Dotan, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.